Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
The European Commission has granted conditional marketing authorisation for…
Vitrakvi (larotrectinib), first ‘histology-independent’ treatment for solid tumours with a specific gene mutation
EMA’s human medicines committee has recommended granting a marketing…